Clinical data | |
---|---|
AHFS/Drugs.com | monograph |
MedlinePlus | a604035 |
Pregnancy cat. | ? |
Legal status | ? |
Routes | Oral |
Identifiers | |
CAS number | 53608-75-6 |
ATC code | A09AA02 |
DrugBank | DB00085 |
UNII | FQ3DRG0N5K |
Chemical data | |
Formula | C5850H8902N1606O1739S49 |
Mol. mass | 131 kDa |
(verify) |
(what is this?)
Pancrelipase is a form of enzyme therapy for the treatment of various digestive disorders, primarily exocrine pancreatic insufficiency. It is a mixture of three digestive enzymes, amylase, trypsin, and lipase, which are normally produced by the pancreas. Pancrelipase is a form of pancreatin having a elevated content of lipase.
Contents |
Pancrelipase is used by patients suffering from cystic fibrosis, chronic pancreatitis and after pancreatectomy.
Brand names for Pancrelipase include Creon, Pancrease, Ultrase, Mezym and Ozym.
Creon is a Pancrelipase manufactured and produce by Abbott Laboratories. Its available in different packaging ie Creon 5, 10 or 20.
Creon 10,000 mini-microspeheres (delayed release capsules) is available in China, Singapore, Malaysia and Thailand with enzyme contains lipase 10,000 u, amylase 8,000 u, protease 600 u.[1]
Its main indication is for patients with pancretic exocrine insufficiency ie, cystic fibrosis, chronic pancreatitis, pancreatectomy, pancreatic cancer and gastrotectomy.
|